Generation of Bacteriodes fragilis capsular polysaccharide A-only producing mutant strain
US9057070B2 · kind B2 · utility
7Cited by
1References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 3, 2012 |
| Grant date | Jun 16, 2015 |
| Priority date | — |
| Expiry date | Oct 3, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12P19/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an isolated B. fragilis bacterial cell producing a native capsular polysaccharide A (PSA), wherein the cell is incapable of producing capsular polysaccharides PSB, PSC, PSD, PSE, PSF, PSG, and PSH because the cell's biosynthetic genes for native capsular polysaccharides PSB, PSC, PSD, PSE, PSF, PSG, and PSH have been deleted from the cell's genome. The isolated or wild type B. fragilis cell, or an extract obtained from said B. fragilis cell, can be used to treat individuals with inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.